GREG CUNY to Drug Evaluation, Preclinical
This is a "connection" page, showing publications GREG CUNY has written about Drug Evaluation, Preclinical.
Connection Strength
0.181
-
Structure-activity relationship study of pyridazine derivatives as glutamate transporter EAAT2 activators. Bioorg Med Chem Lett. 2011 Oct 01; 21(19):5774-7.
Score: 0.093
-
Identification of novel compounds that increase SMN protein levels using an improved SMN2 reporter cell assay. J Biomol Screen. 2012 Apr; 17(4):481-95.
Score: 0.024
-
Improving binding specificity of pharmacological chaperones that target mutant superoxide dismutase-1 linked to familial amyotrophic lateral sclerosis using computational methods. J Med Chem. 2010 Apr 08; 53(7):2709-18.
Score: 0.021
-
RNA therapeutics directed to the non coding regions of APP mRNA, in vivo anti-amyloid efficacy of paroxetine, erythromycin, and N-acetyl cysteine. Curr Alzheimer Res. 2006 Jul; 3(3):221-7.
Score: 0.016
-
FDA-preapproved drugs targeted to the translational regulation and processing of the amyloid precursor protein. J Mol Neurosci. 2004; 24(1):129-36.
Score: 0.014
-
Discovery of inhibitors that elucidate the role of UCH-L1 activity in the H1299 lung cancer cell line. Chem Biol. 2003 Sep; 10(9):837-46.
Score: 0.013